Pegcetacoplan-Empaveli purchase methods and channel recommendations

Pegcetacoplan (Pegcetacoplan), as a rare disease drug, currently has relatively limited access to overseas markets, and its price is usually high. According to public information, the price of 1080mg/20ml Pegtuck in overseas markets is around US$4,700. Since the drug is a biological agent and a complement inhibitor, there are currently no generic drugs on the market, and only original drugs are available for purchase on the market.

When patients or families purchase PegTuck, they usually have several options to choose from. The first is to obtain it through the rare disease drug supply department of local hospitals or professional hematology and nephrology outpatient clinics. Such drugs generally require a doctor's prescription and are reviewed and distributed by the hospital's pharmacy department. The second is to purchase through authorized pharmacies or sales channels of specific pharmaceutical manufacturers, especially in some countries that have special patient assistance programs that can provide purchase convenience or price support. Third, for patients who need long-term use, the medical system in some countries allows home self-injection mode. Patients can purchase drugs through formal channels and complete injections at home under the guidance of a doctor to reduce the frequency of medical visits.

Be aware of storage conditions when purchasing PegTuck. As a biologic, PegTac should be stored refrigerated at 2-8°C to avoid frostbite and exposure to high temperatures, and should be returned to room temperature before injection to ensure stable efficacy. Before use, the appearance of the drug must be carefully inspected to ensure that there are no foreign matter or abnormal precipitation. Since drugs are expensive and are special drugs, it is recommended that patients purchase them through formal medical institutions and officially authorized channels to avoid drug quality risks or safety hazards caused by illegal channels.

In general, although the purchase methods and channels for Pegtak are limited, patients can still obtain safe and effective drugs through formal channels and doctor's guidance. The accessibility of PegTac may be further improved, providing a more stable and sustainable treatment option for patients with PNH and C3G/IC-MPGN.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli